Desogestrel

Known or suspected sex-steroid sensitive malignancies, undiagnosed vaginal bleeding, active venous thromboembolic disorder, acute porphyria. Severe hepatic impairment (active or history). Pregnancy.

Women with breast cancer, liver cancer, functional ovarian cyst; hypertension, history of thromboembolic disorders, previous ectopic pregnancy; diabetes mellitus, severe gastrointestinal disturbances, SLE with positive (or unknown) antiphospholipid antibodies; depression, migraine; history of chloasma gravidarum. Women undergoing prolonged immobilisation due to surgery or illness. Mild to moderate hepatic impairment. Lactation. Monitoring Parameters Screen for pregnancy and perform diagnostic measures for bleeding disturbances (e.g. amenorrhoea, oligomenorrhoea) before initiating treatment. Monitor for amenorrhoea or abdominal pain as it must be considered for the differential diagnosis of ectopic pregnancy; signs and symptoms of depression and breakthrough bleeding.

Significant: Breakthrough bleeding, venous thromboembolism (e.g. DVT, pulmonary embolism), hypertension, SLE, porphyria, chloasma; depressed mood and depression. Eye disorders: Contact lens intolerance. Gastrointestinal disorders: Nausea, vomiting. General disorders and administration site conditions: Fatigue. Investigations: Increased weight. Nervous system disorders: Headache. Pregnancy, puerperium and perinatal conditions: Rarely, ectopic pregnancy. Psychiatric disorders: Mood alterations. Reproductive system and breast disorders: Breast pain, irregular menstruation, amenorrhoea, dysmenorrhoea, ovarian cyst, decreased libido. Skin and subcutaneous tissue disorders: Acne, alopecia.

Decreased contraceptive efficacy with enzyme inducers (e.g. barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, efavirenz, felbamate, griseofulvin, oxcarbazepine, topiramate, and rifabutin). May increase the plasma concentrations with CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, diltiazem). May increase or decrease the plasma concentrations with HIV protease inhibitors (e.g. ritonavir), agents for hepatitis C virus (e.g. boceprevir), and non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine). May increase the plasma and tissue levels of ciclosporin. May decrease the plasma and tissue levels of lamotrigine.

Oral Contraceptives

G03AC09 - desogestrel ; Belongs to the class of progestogens. Used as systemic contraceptives.